CD19 and plasma cell myeloma: These engineered cells can engage a range of target proteins, including CD19, CD20, CD22, GPC3, and B-cell maturation antigen (BCMA).362 Trials using CAR-T cells targeting the B cell antigen CD19 have exhibited a high degree of efficacy against acute lymphocytic leukemia,363–367 chronic lymphocytic leukemia,347,368,369 and non-Hodgkin lymphoma.370–375 Meanwhile, CAR-T cells targeting BCMA have demonstrated activity in multiple myeloma.376–379